Lingxing Biotech and BioMap Announce Strategic Ecosystem Partnership to Advance Intelligent Precision Oncology Drug Development

Shanghai, April 29, 2021 /PRNewswire/ --On April 29, 2021, Lingxing Shengwu Keji and BioMap (Beijing) Intelligent Technology Co., Ltd. (BioMap) announced the establishment of a strategic ecological partnership. The two parties will collaborate in the field of precision oncology by leveraging their respective resources and advantages, working together to advance the intelligent and precise development of clinical oncology drugs based on joint data mining.

Leveraging Lingxing Shengwu Keji’s robust technical expertise and extensive data accumulation in its field, and supported by BioMap’s biological computing engine, the two parties will fully capitalize on their respective strengths to engage in comprehensive ecosystem collaboration across all stages, including scientific research services, research project design, industrial implementation of new technologies, and new product development and commercialization.

Lingxing BiotechBy leveraging CLIA/CAP-accredited clinical laboratory services that meet international standards, comprehensive real-world datasets encompassing whole-genome sequencing, clinical histories, and long-term survival outcomes, a cloud-based open interactive SaaS platform, and proprietary data-driven intelligent algorithms, we empower pharmaceutical companies to efficiently unlock the full potential of their data. We have independently developed and launched the Clinical Intelligence Analysis Platform (CIAP), and provided best-in-class, China-centric real-world study solutions focused on oncology patients to numerous globally renowned pharmaceutical companies, accumulating extensive case studies and practical expertise in this field.

BioMapLeveraging its bio-computational engine, which includes a multi-omics joint mining platform, an AI-driven drug design platform, and a high-throughput in vitro simulation and drug validation platform, BioMap utilizes artificial intelligence to accelerate the translation of novel targets and drug development. In collaboration with Lingxing Shengwu Keji, BioMap jointly selects targets or biomarkers with significant development potential and translational prospects for co-development and technology transfer.

Both Liu Wei, CEO of BioMap, and Dr. Xu Qiang, CEO of Lingxing Shengwu Keji, expressed strong endorsement and appreciation for this strategic ecosystem partnership.

BioMapCEO Liu Wei stated:

The emergence of biotechnology has brought about a massive amount of biological information data, and how to effectively utilize and manage this data is a significant challenge. Lingxing Shengwu Keji is the first company in China to provide real-world data solutions, with extensive experience in exploring real-world data research among Chinese cancer patients. As China’s first bio-computation-driven life sciences platform company, we are delighted to establish a comprehensive ecological partnership with Lingxing Shengwu Keji. By leveraging AI and computational capabilities for data mining, we aim to jointly advance the clinical progress and scientific transformation of innovative drugs.

Lingxing BiotechDr. Xu Qiang, CEO, stated:

BioMap is China’s first life sciences platform company driven by biological computing technology, committed to building a top-tier domestic and internationally leading ecosystem. Lingxing Shengwu Keji has been dedicated to leveraging artificial intelligence and data algorithms to correlate molecular mechanisms, patient populations, and clinical significance, while exploring the research mechanisms of clinical translation and reverse translation among these three elements. This approach aims to fulfill its vision of helping patients receive precision therapy and supporting pharmaceutical companies in precise drug development. We look forward to collaborating with BioMap to harness artificial intelligence technologies to empower the R&D of novel oncology drugs, thereby delivering tangible benefits to cancer patients in China.

Looking ahead, Lingxing Shengwu Keji will build upon the deepened strategic partnership between both parties, leverage its data and technological advantages, and continue to deepen its engagement in cancer translational research and clinical development of oncology drugs. By providing robust real-world data solutions, it aims to accelerate the development and promotion of innovative oncology therapeutics, thereby facilitating the comprehensive intelligent transformation of precision drug development for cancer in China.